Clinical Presentation and Triggering Factors
The classic presentation of a gouty attack manifests as sudden acute pain, most commonly affecting a single joint (the knee is a typical example, though others may be involved). The development of such pain rarely occurs without an apparent cause; the attack is usually preceded by specific triggers. Among the most frequent inciting factors are exposure to low temperatures (hypothermia) and unusual or intense physical exertion.
Locally, the area of the affected joint consistently displays classic signs of active inflammation. Physical examination reveals marked erythema (redness of the skin) and significant swelling of the surrounding soft tissues. Laboratory blood tests identify the key marker of the disease — hyperuricemia, which is a pathologic elevation in uric acid concentration.
Pharmacotherapy: Drugs for Acute Attack Management
The primary objective of treatment in the acute phase is to interrupt the inflammatory cascade as rapidly as possible and ensure adequate analgesia. A strictly defined pool of medications is used to achieve this goal:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs). These serve as the baseline therapy. A typical representative of this class actively used for pain and inflammation relief in gout is ibuprofen.
- Colchicine (Colchicinum). A specific medication successfully used both for the prevention of recurrent gout flares and for the effective management of acute attacks already underway.
- Interleukin-1 Blockers. Considered as potential alternative or adjunctive therapeutic options. A prominent example from this class is anakinra.
Pharmacodynamics of Colchicine
The specific therapeutic action of Colchicinum differs radically from conventional analgesics. Its mechanism of action is based on intracellular interference: the drug selectively disrupts the normal interaction of $\alpha$- and $\beta$-tubulin molecules. Consequently, the microtubules of the cellular cytoskeleton are disrupted, preventing the proper migration of immune cells to the site of inflammation.
It is important to note colchicine's high specificity. It is not a universal agent and is not used to treat arthritis of any other etiology. Furthermore, unlike many other anti-inflammatory drugs, the mechanism of action of colchicine is entirely unrelated to COX-2 inhibition or macrophage Toll-like receptor signaling.
Limitations and Common Pitfalls in the Acute Phase
When managing a patient with an acute attack, it is necessary to avoid prescribing certain medications that may prove useless or even harmful during this period.
Drugs that directly affect uric acid metabolism (such as allopurinol) are not intended for analgesia and are not first-line agents in the acute phase of inflammation. Diuretics (such as hydrochlorothiazide) should also be avoided, as they do not help relieve the attack and may be completely contraindicated during an acute gouty flare.